The treatment of melanoma cells with these agents increased the protein levels of YAP/TAZ, coupled with the activation of YAP/TAZ target genes, such as connective tissue growth factor (CTGF), baculoviral IAP repeat containing 5 (BIRC5), cysteine rich angiogenic Inducer 61 (CYR61), and TEA domain transcription factor 4 (TEAD4). The gene discussed is CCN2; the disease is melanoma.